Objective To investigate the value of Fibroscan and aspartate aminotransferase (AST) to platelet ratio index(APRI) in the diagnosis of liver fibrosis in patients with chronic hepatitis B (CHB) complicated with fatty liver.Methods CHB patients with fatty liver from January to December 2017 in Yangjiang Public Health Hospital were selected,and 46 cases were selected for retrospective analysis.The patients were all performed Fibroscan and APRI detection.The patients were followed up for 2 years to observe the fibrosis of the patients at this stage and to monitor their condition.Results There was no significant difference between Fibroscan and APRI in the detection rate of different degrees of fibrosis and pathological detection (P＞0.05).After 2 years of treatment, the APRI, Fibroscan, AST indexes were lower than the initial value, the differences were statistically significant (P＜0.05).While there was no significant difference in the blood platelet indexes between after 2 years of treatment and initial value (P＞0.05).With the aggravation of liver fibrosis, the detection of APRI and Fibroscan increased.Conclusion The combination of Fibroscan and APRI in CHB patients with fatty liver can comprehensively analyze the changes in liver fibrosis, and dynamically monitor the disease, which has a positive significance for disease monitoring and can improve the quality of comprehensive interventions, is conducive to the treatment of later disease.